Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04001413
Title Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

oropharynx cancer

Therapies

Durvalumab

Durvalumab + MEDI0457

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.